X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (5404) 5404
Publication (337) 337
Newsletter (131) 131
Book Review (56) 56
Magazine Article (39) 39
Newspaper Article (12) 12
Dissertation (9) 9
Book Chapter (6) 6
Trade Publication Article (6) 6
Conference Proceeding (3) 3
Book / eBook (2) 2
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
salmeterol (3482) 3482
humans (3478) 3478
male (1957) 1957
albuterol - analogs & derivatives (1927) 1927
asthma (1906) 1906
salmeterol xinafoate (1889) 1889
respiratory system (1877) 1877
female (1852) 1852
asthma - drug therapy (1670) 1670
index medicus (1617) 1617
administration, inhalation (1462) 1462
middle aged (1381) 1381
adult (1294) 1294
fluticasone (1110) 1110
bronchodilator agents - therapeutic use (1102) 1102
albuterol - therapeutic use (1084) 1084
pulmonary disease, chronic obstructive - drug therapy (1049) 1049
aged (1040) 1040
bronchodilator agents - administration & dosage (987) 987
albuterol - administration & dosage (913) 913
double-blind method (900) 900
formoterol (888) 888
treatment outcome (883) 883
obstructive pulmonary-disease (843) 843
pharmacology & pharmacy (843) 843
drug therapy, combination (840) 840
copd (767) 767
fluticasone propionate (700) 700
drug therapy (694) 694
chronic obstructive pulmonary disease (688) 688
adolescent (651) 651
adrenergic beta-agonists - therapeutic use (650) 650
medicine, general & internal (634) 634
inhaled corticosteroids (597) 597
formoterol fumarate (590) 590
lung diseases, obstructive (588) 588
exacerbations (580) 580
drug combinations (565) 565
salbutamol (553) 553
corticosteroids (544) 544
tiotropium (535) 535
allergy (526) 526
budesonide (509) 509
asthma - physiopathology (501) 501
androstadienes - administration & dosage (489) 489
adrenergic beta-agonists - administration & dosage (487) 487
child (483) 483
pulmonary disease, chronic obstructive - physiopathology (465) 465
bronchodilator agents - adverse effects (436) 436
androstadienes - therapeutic use (435) 435
albuterol - pharmacology (430) 430
immunology (413) 413
adrenal cortex hormones - administration & dosage (399) 399
dose-response relationship, drug (392) 392
forced expiratory volume - drug effects (388) 388
efficacy (382) 382
cross-over studies (374) 374
albuterol - adverse effects (373) 373
therapy (373) 373
anti-asthmatic agents - therapeutic use (372) 372
quality of life (372) 372
double-blind (364) 364
research (360) 360
care and treatment (357) 357
forced expiratory volume (355) 355
ethanolamines - administration & dosage (346) 346
time factors (338) 338
cardiac & cardiovascular systems (337) 337
anti-asthmatic agents - administration & dosage (330) 330
albuterol (320) 320
dosage and administration (319) 319
tiotropium bromide (318) 318
adrenal cortex hormones - therapeutic use (316) 316
ethanolamines - therapeutic use (308) 308
safety (304) 304
adrenergic beta-agonists - pharmacology (302) 302
respiratory function tests (302) 302
animals (300) 300
severity of illness index (297) 297
randomized controlled trials as topic (295) 295
lung-function (294) 294
mortality (292) 292
children (287) 287
analysis (285) 285
respiratory tract diseases (276) 276
drug administration schedule (275) 275
inflammation (274) 274
adrenergic beta-agonists - adverse effects (269) 269
fluticasone-salmeterol drug combination (268) 268
pulmonary and respiratory medicine (263) 263
aged, 80 and over (262) 262
salmeterol/fluticasone propionate (261) 261
bronchodilator agents - pharmacology (257) 257
nebulizers and vaporizers (255) 255
pulmonary/respiratory (252) 252
persistent asthma (243) 243
risk factors (231) 231
combination (225) 225
antiasthmatic agents (223) 223
management (222) 222
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (5217) 5217
German (109) 109
French (86) 86
Spanish (45) 45
Japanese (27) 27
Polish (27) 27
Italian (25) 25
Chinese (23) 23
Portuguese (11) 11
Danish (9) 9
Russian (8) 8
Romanian (4) 4
Dutch (3) 3
Czech (2) 2
Korean (2) 2
Norwegian (2) 2
Swedish (2) 2
Turkish (2) 2
Hebrew (1) 1
Hungarian (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


LANCET, ISSN 0140-6736, 09/2016, Volume 388, Issue 10048, pp. 963 - 973
Background Few data are available for the efficacy of "triple therapy" with two long-acting bronchodilators and an inhaled corticosteroid in chronic... 
POPULATION | MEDICINE, GENERAL & INTERNAL | LUNG-FUNCTION | EXACERBATIONS | INDIVIDUAL COMPONENTS | TIOTROPIUM | FLUTICASONE PROPIONATE/SALMETEROL | GLYCOPYRRONIUM | COPD | SALMETEROL | SALMETEROL/FLUTICASONE
Journal Article
Value in Health : The Journal of the International Society for Pharmacoeconomics and Outcomes Research, ISSN 1098-3015, 10/2017, Volume 20, Issue 9, p. A889
Journal Article
The New England Journal of Medicine, ISSN 0028-4793, 06/2016, Volume 374, Issue 23, pp. 2222 - 2234
Journal Article
Respirology, ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 176 - 177
Journal Article
Respirology, ISSN 1323-7799, 11/2017, Volume 22, Issue S3, pp. 178 - 178
Journal Article
Cochrane database of systematic reviews (Online), ISSN 1469-493X, 2012, Volume 2012, Issue 9, p. CD006829
Background Both inhaled steroids (ICS) and long-acting beta(2)-agonists (LABA) are used in the management of chronic obstructive pulmonary disease (COPD). This... 
Adrenal Cortex Hormones [administration & dosage; adverse effects] | COST-EFFECTIVENESS | Adrenergic beta-Agonists [administration & dosage; adverse effects] | CLINICAL-TRIAL | Humans | FLUTICASONE PROPIONATE/SALMETEROL 250/50 | SALMETEROL/FLUTICASONE PROPIONATE | COPD EXACERBATIONS | LUNG-FUNCTION | RANDOMIZED CONTROLLED-TRIAL | Pneumonia [chemically induced] | Randomized Controlled Trials as Topic | SALMETEROL | Bronchodilator Agents [administration & dosage; adverse effects] | Pulmonary Disease, Chronic Obstructive [drug therapy; mortality] | MEDICINE, GENERAL & INTERNAL | METERED-DOSE INHALER | Quality of Life | Adult | Drug Therapy, Combination | 50 MU-G | Drug Combinations | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - mortality | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Fluticasone | Ethanolamines - administration & dosage | Pneumonia - chemically induced | Adrenergic beta-Agonists - administration & dosage | Albuterol - administration & dosage | Bronchodilator Agents - adverse effects | Adrenergic beta-Agonists - adverse effects | Salmeterol Xinafoate | Albuterol - analogs & derivatives | Adrenal Cortex Hormones - adverse effects | Drug Therapy, Combination - methods | Androstadienes - administration & dosage | Budesonide - adverse effects | Budesonide - administration & dosage | Androstadienes - adverse effects | Albuterol - adverse effects | Adrenal Cortex Hormones - administration & dosage | Pulmonary Disease, Chronic Obstructive - drug therapy
Journal Article
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents
Journal Article
THORAX, ISSN 0040-6376, 06/2015, Volume 70, Issue 6, pp. 519 - 527
Background The optimal use of various therapeutic combinations for moderate/severe chronic obstructive pulmonary disease (COPD) is unclear. The GLISTEN trial... 
PROPIONATE | INDACATEROL | MODERATE | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | EFFICACY | RESPIRATORY SYSTEM | COPD Pharmacology | TIOTROPIUM | FLUTICASONE PROPIONATE/SALMETEROL | COMBINATION | SALMETEROL
Journal Article
American Journal of Respiratory and Critical Care Medicine, ISSN 1073-449X, 05/2017, Volume 195, Issue 9, pp. 1189 - 1197
Journal Article
The Cochrane database of systematic reviews, ISSN 1469-493X, 2013, Volume 5, Issue 5, p. CD007891
Journal Article
Thorax, ISSN 0040-6376, 11/2006, Volume 61, Issue 11, pp. 940 - 944
Background: The homozygous presence of the arginine-16 variant of the β2 adrenoceptor gene ADRB2 reverses the benefits from the regular use of short acting β2... 
polymorphism | ADRB2 | children | salmeterol | Asthma
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 210 - 223
Journal Article